S.Biomedics Co., Ltd. (KOSDAQ:304360)
South Korea · Delayed Price · Currency is KRW 36,850
+2,250 (6.50%)
At close: Apr 29, 2026
S.Biomedics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 16,548 | 13,734 | 13,108 | 12,113 | 8,868 |
Other Revenue | - | - | - | -0 | - |
| 16,548 | 13,734 | 13,108 | 12,113 | 8,868 | |
Revenue Growth (YoY) | 20.49% | 4.77% | 8.22% | 36.59% | 66.72% |
Cost of Revenue | 9,001 | 7,027 | 6,555 | 6,002 | 4,549 |
Gross Profit | 7,547 | 6,707 | 6,554 | 6,111 | 4,319 |
Selling, General & Admin | 5,797 | 5,665 | 5,414 | 4,224 | 3,357 |
Research & Development | 9,179 | 5,850 | 6,508 | 5,489 | 5,525 |
Amortization of Goodwill & Intangibles | 7.95 | 5.39 | 5.06 | 9.07 | 9.49 |
Operating Expenses | 15,891 | 12,149 | 12,543 | 9,863 | 8,947 |
Operating Income | -8,344 | -5,442 | -5,989 | -3,752 | -4,628 |
Interest Expense | -1,451 | -795.15 | -883.54 | -727.42 | -674.93 |
Interest & Investment Income | 369.52 | 310.05 | 266.24 | 146.72 | 101.05 |
Currency Exchange Gain (Loss) | -22.05 | 83.95 | 39.53 | 17.21 | 91.56 |
Other Non Operating Income (Expenses) | 2,528 | -159.85 | -2,665 | -918.38 | -151.52 |
EBT Excluding Unusual Items | -6,919 | -6,003 | -9,232 | -5,234 | -5,262 |
Gain (Loss) on Sale of Investments | 105.87 | 76.12 | 92.61 | 23.87 | 0.24 |
Gain (Loss) on Sale of Assets | - | - | 5.49 | - | - |
Other Unusual Items | 4.06 | 169.48 | -0.48 | - | 12.82 |
Pretax Income | -6,809 | -5,757 | -9,134 | -5,210 | -5,249 |
Income Tax Expense | 250.51 | 63.79 | 123.24 | -455.23 | -6.59 |
Earnings From Continuing Operations | -7,059 | -5,821 | -9,258 | -4,755 | -5,242 |
Minority Interest in Earnings | -1,063 | -869.84 | -1,063 | -1,572 | -424.81 |
Net Income | -8,122 | -6,691 | -10,321 | -6,327 | -5,667 |
Net Income to Common | -8,122 | -6,691 | -10,321 | -6,327 | -5,667 |
Shares Outstanding (Basic) | 12 | 12 | 11 | 10 | 10 |
Shares Outstanding (Diluted) | 12 | 12 | 11 | 10 | 10 |
Shares Change (YoY) | 3.22% | 5.22% | 6.97% | 0.67% | 0.42% |
EPS (Basic) | -684.07 | -581.66 | -944.09 | -619.09 | -558.24 |
EPS (Diluted) | -684.07 | -581.66 | -944.09 | -619.09 | -558.24 |
Free Cash Flow | -8,584 | -4,890 | -7,996 | -12,501 | -3,762 |
Free Cash Flow Per Share | -722.99 | -425.15 | -731.44 | -1223.19 | -370.56 |
Gross Margin | 45.61% | 48.84% | 50.00% | 50.45% | 48.70% |
Operating Margin | -50.42% | -39.62% | -45.69% | -30.98% | -52.19% |
Profit Margin | -49.08% | -48.72% | -78.73% | -52.23% | -63.90% |
Free Cash Flow Margin | -51.88% | -35.61% | -61.00% | -103.20% | -42.42% |
EBITDA | -6,301 | -3,717 | -4,436 | -2,235 | -3,180 |
EBITDA Margin | -38.08% | -27.06% | -33.84% | -18.45% | -35.86% |
D&A For EBITDA | 2,043 | 1,725 | 1,553 | 1,517 | 1,448 |
EBIT | -8,344 | -5,442 | -5,989 | -3,752 | -4,628 |
EBIT Margin | -50.42% | -39.62% | -45.69% | -30.98% | -52.19% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.